Dyne Therapeutics: Insider Ownership Change Reported
Ticker: DYN · Form: 4 · Filed: Apr 27, 2026 · CIK: 0001818794
| Field | Detail |
|---|---|
| Company | Dyne Therapeutics, Inc. (DYN) |
| Form Type | 4 |
| Filed Date | Apr 27, 2026 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: insider-transaction, ownership-change
TL;DR
Rhodes updated his Dyne Therapeutics holdings on 4/23/26. Details pending.
AI Summary
On April 23, 2026, Jason P. Rhodes reported a change in beneficial ownership of securities for Dyne Therapeutics, Inc. The filing details transactions related to his holdings, but specific dollar amounts and the exact nature of the transactions are not provided in this excerpt.
Why It Matters
Changes in beneficial ownership by insiders can signal their confidence in the company's future prospects, potentially influencing investor sentiment.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of changes in beneficial ownership and does not inherently indicate increased risk.
Key Players & Entities
- Dyne Therapeutics, Inc. (company) — Issuer
- Jason P. Rhodes (person) — Reporting Person
- 0001577014-26-000004 (filing_id) — SEC Accession Number
- 2026-04-27 (date) — Filing Date
- 2026-04-23 (date) — Period of Report
FAQ
Who is the reporting person and what is their role?
The reporting person is Jason P. Rhodes, and their role is listed as 'Reporting'.
What is the company involved in this filing?
The company involved is Dyne Therapeutics, Inc.
What type of form is this SEC filing?
This is a Form 4 - Statement of changes in beneficial ownership of securities.
When was the filing accepted by the SEC?
The filing was accepted on 2026-04-27.
What is the period of report for this filing?
The period of report is 2026-04-23.
Filing Details
This Statement of Changes in Beneficial Ownership (Form 4) was filed with the SEC on April 27, 2026 by Jason P. Rhodes regarding Dyne Therapeutics, Inc. (DYN). Form 4 filings disclose purchases, sales, or other changes in ownership by company insiders such as officers, directors, and major shareholders.